

RespireRx Pharmaceuticals

10:32 09 Aug 2023

RespireRx to transfer cannabinoid research program to Australian subsidiary ResolutionRx

RespireRx Pharmaceuticals (OTC:RSPI) shares rose on Wednesday morning after it announced that it has entered into agreements with its Australian subsidiary ResolutionRx to transfer RespireRx's pharmaceutical cannabinoid program to ResolutionRx and establish it as an operating company.

Once RespireRx has transferred its cannabinoid drug development program to ResolutionRx, the latter will engage in research and development associated with that program, initially for the development of a new formulation of dronabinol for use in a Phase 3 clinical trial and the filing of regulatory approval for the treatment of obstructive sleep apnea.

In consideration, ResolutionRx issued 25 million of its shares to RespireRx plus US\$1.

Additionally, ResolutionRx has confirmed the pricing of its previously disclosed securities offering for Series A Preference Shares after entering agreements with Cantheon Capital and PrimaryMarkets earlier this year.

The established price is 90% of a US\$25 million value, which amounts to US\$22.5 million, based on an independent valuation and aligning with the terms of the agreements.

"Since the incorporation of ResolutionRx at the beginning of this year, it has been our intention to restructure RespireRx by creating a fully operational, cannabinoid drug research and development entity in Australia that will have adequate capital to conduct its strategic and operational plans," RespireRx CFO Jeff Margolis said.

ResolutionRx chief scientific officer Arnold Lipka added: "Our established relationships with our Australian-based law firm, our commercial bank, our Australian-based accountants and financial advisory firm as well as the previously announced term sheet and letter of intent for a debt facility to be provided by Radium Capital to finance 80% of ResolutionRx's anticipated 43.5% of the Australian research and development tax incentive, and the previously disclosed letter of intent with Cantheon Capital have guided us to a pathway."

He added that ResolutionRx's service agreements with RespireRx and Australian contract research organization iNGENU will provide the needed infrastructure for its operations, which he noted have recently begun.


"Finally, the receipt of an independent valuation analysis has enabled us to establish the price for the Cantheon letter of intent and for the PrimaryMarkets offering at US\$0.90 per Series A Share, equivalent to 90% of a US\$25 million maximum negotiated value," he added.

"We believe that these developments confirm our restructuring strategy to realize the intrinsic worth of our assets and,

Price: 0.0013

Market Cap: \$204.14 k

1 Year Share Price Graph



August 2022 February 2023 August 2023

Share Information

Code: RSPI

Listing: OTC

52 week	High	Low
	0.0191	0.0011

Sector: Pharma & Biotech

Website: respirerx.com

Company Synopsis:

RespireRx Pharmaceuticals Inc is a biopharmaceutical company developing innovative and revolutionary treatments to combat disorders caused by disruption of neuronal signaling.

action@proactiveinvestors.com

in turn, increase shareholder value."

RespireRx shares had added 25% at US\$0.0015 on Wednesday morning.

Contact the author at emily.jarvie@proactiveinvestors.com

Follow her on Twitter [@emilyjarvie](https://twitter.com/emilyjarvie)

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

This record is published on behalf of RespireRx Pharmaceuticals, which is a paid client of ProactiveInvestors. You understand that ProactiveInvestors receives either monetary or securities compensation for our services, including for publishing articles, newswires, reports and other records by or on behalf of clients who are issuers or securityholders of issuers. Although Proactive Investors' compensation is not tied to the completion of any financing or sale of any securities, we stand to benefit from any volume such write-ups may generate.

ProactiveInvestors is a publisher. You understand and agree that no content in this record or published on ProactiveInvestors' website (the "Site") constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person and that no such content is tailored to any specific person's needs. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell products or securities.

The Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to ProactiveInvestors. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to ProactiveInvestors, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, ProactiveInvestors, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.